Skip to main content
SpringerLink
Log in

The value of serum Bcl-2 levels in advanced lung cancer patients

  • Original Article
  • Published:
Medical Oncology Aims and scope Submit manuscript

Abstract

Overexpression of the Bcl-2 protein was associated with a favorable prognostic factor for survival in lung cancer patients, especially nonsmall cell lung carcinoma. The present study was conducted to investigate the value of serum Bcl-2 levels in advanced lung cancer patients. Fifty patients with advanced lung carcinoma pathologically verified and 18 healthy controls were investigated. Serum samples were obtained on the first admission before the chemotherapeutic treatment were given. Serum Bcl-2 levels were determined by using anti-Bcl-2 monoclonal coating antibody. The baseline serum Bcl-2 levels were significantly higher in patients with lung cancer than in the control group (p<0.001). Serum Bcl-2 levels were elevated in 48 (96%) advanced lung cancer patients. None of the prognostic parameters analyzed, such as age of patient, gender, histology, stage of disease, erythrocyte sedimentation rate, serum albumin, hemoglobin, CEA, NSE, LDH, performance of patient, weight loss, and response to chemotherapy, was significantly correlated with Bcl-2 serum concentrations. The serum Bcl-2 concentrations were not changed with cisplatin-based cytotoxic chemotherapy regardless of response (p=0.76). No prognostic value of serum Bcl-2 was determined. In conclusion, the results of the present study, which is the first study to determine serum Bcl-2 levels in lung cancer, suggest that decreased apoptosis occurred due to the effect of serum Bcl-2 elevation in lung cancer patients. Serum Bcl-2 level was of diagnostic but not prognostic value in lung cancer patients. However, more studies are needed to define the role of Bcl-2 in the diagnosis and prognosis of lung cancer.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Jong D, Prins FA, Masson DY, Reed JC, Van Ommen GB, Kluin PM. Subcellular localization of the bcl-2 protein in malignant and normal lymphoid cells. Cancer Res 1994; 54:256–260.

    PubMed  Google Scholar 

  2. Martin B, et al. Role of Bcl-2 as a prognostic factor for survival in lung cancer: a systematic review of the literature with meta-analysis. Br J Cancer 2003; 89: 55–64.

    Article  PubMed  CAS  Google Scholar 

  3. Silvestrini R, et al. The bcl-2: a prognostic indicator strongly related to p53 protein in lymph node-negative breast cancer patients. J Natl Cancer Inst 1994; 86: 499–504.

    Article  PubMed  CAS  Google Scholar 

  4. Colombel M, et al. Detection of the apoptosis-suppressing oncoprotein bcl-2 in hormone-refractory human prostate cancers. Am J Pathol 2000; 143: 390–400.

    Google Scholar 

  5. Fontanini G, et al. Bcl-2 protein: a prognostic factor inversely correlated to p53 in non-small-cell lung cancer. Br J Cancer 1995; 71: 1003–1007.

    Article  PubMed  CAS  Google Scholar 

  6. Shivapurkar N, Reddy J, Chaudhary PM, Gazdar AF. Apoptosis and lung cancer: a review. J Cell Biochem 2003; 88: 885–898.

    Article  PubMed  CAS  Google Scholar 

  7. Gregorc V, et al. The clinical relevance of Bcl-2, Rb and p53 expression in advanced non-small cell lung cancer. Lung Cancer 2003; 42: 275–281.

    Article  PubMed  Google Scholar 

  8. Laudanski J, Niklinska W, Burzykowski T, Chyczewski L, Niklinski J. Prognostic significance of p53 and bcl-2 abnormalities in operable nonsmall cell lung cancer. Eur Respir J 2001; 17: 660–666.

    Article  PubMed  CAS  Google Scholar 

  9. Kaiser U, et al. Expression of bcl-2 protein in small cell lung cancer. Lung Cancer 1996; 15: 31–40.

    Article  PubMed  CAS  Google Scholar 

  10. Kumar Biswas S, Huang J, Persaud S, Basu A. Down-regulation of Bcl-2 is associated with cisplatin resistance in human small cell lung cancer H69 cells. Mol Cancer Ther 2004; 3: 327–334.

    PubMed  CAS  Google Scholar 

  11. Groeger AM, et al. Prognostic value of immunohistochemical expression of p53, bax, Bcl-2 and Bcl-xL in resected non-small-cell lung cancers. Histopathology 2004; 44: 54–63.

    Article  PubMed  CAS  Google Scholar 

  12. Han JY, et al. Death receptor 5 and Bcl-2 protein expression as predictors of tumor response to gemcitabine and cisplatin in patients with advanced non-small-cell lung cancer. Med Oncol 2003; 20: 355–362.

    Article  PubMed  CAS  Google Scholar 

  13. Fokkema E, Groen HJ, Meijer C, Timens W, de Jong S, de Vries EG. The role of apoptosis-related genes in non-small-cell lung cancer. Clin Lung Cancer 2002; 4: 174–182.

    Article  PubMed  CAS  Google Scholar 

  14. Fennell DA. Bcl-2 as a target for overcoming chemoresistance in small-cell lung cancer. Clin Lung Cancer 2003; 4: 307–313.

    Article  PubMed  CAS  Google Scholar 

  15. Zereu M, Vinholes JJ, Zettler CG. P53 and Bcl-2 protein expression and its relationship with prognosis in small-cell lung cancer. Clin Lung cancer 2003; 4: 298–303.

    Article  PubMed  CAS  Google Scholar 

  16. Tomita M, Matsuzaki Y, Edagawa M, Shimizu T, Hara M, Onitsuka T. Prognostic significance of bcl-2 expression in resected pN2 non-small cell lung cancer. Eur J Surg Oncol 2003; 29: 654–657.

    Article  PubMed  CAS  Google Scholar 

  17. Huang CI, Neuberg D, Johnson BE, Wei JY, Christiani DC. Expression of bcl-2 protein is associated with shorter survival in nonsmall cell lung carcinoma. Cancer 2003; 98: 135–143.

    Article  PubMed  CAS  Google Scholar 

  18. Harada T, et al. Predictive value of expression pf p53, Bcl-2 and lung resistance-related protein for response to chemotherapy in non-small cell lung cancers. Cancer Sci 2003; 94: 394–399.

    Article  PubMed  CAS  Google Scholar 

  19. Grossi F, et al. Prognostic significance of K-ras, p53, bcl-2, PCNA, CD34 in radically resected non-small cell lung cancers. Eur J Cancer 2003; 39: 1242–1250.

    Article  PubMed  CAS  Google Scholar 

  20. Krug LM, Miller VA, Filippa DA, Venkatraman E, Ng KK, Kris MG. Bcl-2 and bax expression in advanced non-small cell lung cancer: lack of correlation with chemotherapy response or survival in patients treated with docetaxel plus vinorelbine. Lung Cancer 2003; 39: 139–143.

    Article  PubMed  Google Scholar 

  21. Lai RS, Wang JS, Hsu HK, Chang HC, Lin CH, Lin MH. Prognostic evaluation of the expression of p53 and bcl-2 oncoproteins in patients with surgically resected non-small cell lung cancer. Jpn J Clin Oncol 2002; 32: 393–397.

    Article  PubMed  Google Scholar 

  22. Bubb RS, et al. Association of Ki-67, p53, and bcl-2 expression of the primary non-small-cell lung cancer lesion with brain metastatic lesion. Int J Radiat Oncol Biol Phys 2002; 53: 1216–1224.

    Article  PubMed  CAS  Google Scholar 

  23. Hanaoka T, Nakayama J, Haniuda M, Sato TA. Immunohistochemical demonstration of apoptosis-regulated proteins, Bcl-2 and Bax, in resected non-small-cell lung cancers. Int J Clin Oncol 2002; 7: 152–158.

    Article  PubMed  CAS  Google Scholar 

  24. Ferron PE, Bagni I, Guidoboni M, Beccati MD, Nenci I. Combined and sequential expression of p53, Rb, Ras and Bcl-2 in bronchial preneoplastic lesions. Tumori 1997; 83: 587–593.

    PubMed  CAS  Google Scholar 

  25. Kalomenidis I, et al. Combined expression of p53, Bcl-2, and p21WAF-1 proteins in lung cancer and premalignant lesions: association with clinical characteristics. Lung 2001; 179: 265–278.

    Article  PubMed  CAS  Google Scholar 

  26. Joseph B, Ekedahl J, Sirzen F, Lewensohn R, Zhivotovsky B. Differences in expression of pro-caspases in small cell and non-small cell lung carcinoma. Biochem Biophys Res Commun 1999; 262: 381–387.

    Article  PubMed  CAS  Google Scholar 

  27. Soini Y, Paakko P, Lehto VP. Histopathological evaluation of apoptosis in cancer. Am J Pathol 1998; 153: 1041–1053.

    Article  PubMed  CAS  Google Scholar 

  28. Joseph B, Lewensohn R, Zhivotovsky B. Role of apoptosis in the response of lung carcinomas to anti-cancer treatment. Ann N Y Acad Sci 2000; 926: 204–216.

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Institute of Oncology, University of Istanbul, Turkey

    Faruk Tas, Derya Duranyildiz, Hilal Oguz, Hakan Camlica, Ethem Nezih Oral, Vildan Yasasever & Erkan Topuz

Authors
  1. Faruk Tas
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Derya Duranyildiz
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Hilal Oguz
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Hakan Camlica
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Ethem Nezih Oral
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Vildan Yasasever
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Erkan Topuz
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Faruk Tas.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Tas, F., Duranyildiz, D., Oguz, H. et al. The value of serum Bcl-2 levels in advanced lung cancer patients. Med Oncol 22, 139–143 (2005). https://doi.org/10.1385/MO:22:2:139

Download citation

  • Received:

  • Accepted:

  • Issue Date:

  • DOI: https://doi.org/10.1385/MO:22:2:139

Key Words

Search

Navigation